questionnair
design
assess
capac
qualiti
oper
specif
relat
diagnost
well
barrier
implement
laboratori
part
european
centr
diseas
control
prevent
ecdc
associ
european
expert
laboratori
network
emerg
viral
diseas
evdlabnet
andor
european
refer
laboratori
network
human
influenza
erlinet
survey
sent
januari
oper
contact
point
repres
laboratori
among
other
eueea
countri
survey
subsequ
close
januari
figur
indic
data
valid
individu
email
exchang
laboratori
includ
one
entri
per
laboratori
entri
laboratori
outsid
eueea
veterinari
laboratori
omit
analysi
report
total
data
provid
laboratori
eueea
countri
taken
account
studi
countri
level
eueea
countri
alreadi
implement
molecular
test
laboratori
remain
six
countri
arrang
ship
clinic
specimen
suspect
case
specialis
laboratori
abroad
plan
implement
assay
januari
februari
laboratori
level
respond
laboratori
implement
molecular
diagnost
survey
submiss
eight
nine
remain
laboratori
plan
test
implement
midfebruari
figur
nineteen
laboratori
indic
capac
perform
whole
genom
sequenc
clinic
sampl
laboratori
could
perform
partial
sequenc
laboratori
ask
indic
weekli
capac
molecular
test
figur
overal
laboratori
current
capac
indic
minimum
test
per
week
eight
laboratori
process
implement
molecular
diagnost
would
combin
add
minimum
capac
test
per
week
process
would
complet
fortyf
laboratori
countri
indic
previou
expertis
human
coronaviru
hcov
diagnost
two
countri
two
respond
laboratori
experi
twentyf
laboratori
countri
indic
experi
molecular
diagnost
six
addit
hcov
middl
east
respiratori
syndrom
cov
sever
acut
respiratori
syndrom
cov
fortyfour
laboratori
countri
perform
differenti
test
common
respiratori
pathogen
viral
bacteri
origin
overal
survey
respond
indic
abil
process
wide
rang
respiratori
sampl
type
includ
nasopharyng
swab
n
bronchoalveolar
lavag
n
oropharyng
swab
n
nasopharyng
aspir
n
sputum
n
endo
tracheal
aspir
n
nasal
wash
n
addit
number
respond
indic
laboratori
could
process
biopsi
materi
n
whole
blood
plasma
serum
n
detect
biosafetylevel
bsl
appli
inactiv
clinic
sampl
suspect
laboratori
eueea
laboratori
indic
twentyon
laboratori
indic
four
laboratori
indic
intermedi
level
extra
precaut
wear
filter
face
piec
ffp
mask
differ
approach
observ
laboratori
within
countri
januari
protocol
rtpcr
publish
websit
survey
closur
januari
envelop
e
gene
screen
test
publish
corman
et
al
implement
laboratori
confirmatori
rnadepend
rna
polymeras
rdrp
gene
test
nucleoprotein
n
gene
test
respect
laboratori
sixteen
laboratori
indic
addit
test
ie
hous
test
n
pancov
test
n
assay
base
poon
et
al
n
two
laboratori
indic
base
test
sole
previous
publish
pancov
test
laboratori
laboratori
implement
test
indic
valid
specif
implement
test
six
addit
known
hcov
common
respiratori
pathogen
laboratori
specif
valid
still
progress
time
data
submiss
seven
laboratori
indic
partial
valid
implement
test
five
laboratori
yet
perform
valid
questionnair
send
first
case
appear
europ
figur
posit
clinic
specimen
assum
avail
european
laboratori
therefor
level
valid
clinic
sensit
assess
three
laboratori
implement
diagnost
implement
without
posit
control
indic
sourc
posit
control
european
viru
archiv
evag
synthet
egen
sarscov
rna
n
stock
ie
sarshcov
rna
andor
synthet
rna
n
top
three
challeng
experienc
test
implement
initi
lack
posit
control
lack
personneltim
lack
primer
andor
probe
figur
nine
laboratori
eight
countri
indic
obstacl
februari
confirm
case
report
eight
european
countri
base
ecdc
report
test
criteria
multipl
model
studi
estim
risk
introduct
europ
high
pullano
et
al
indic
unit
kingdom
franc
germani
highest
risk
follow
itali
spain
netherland
inde
one
countri
netherland
report
case
studi
report
occurr
import
beij
shanghai
citi
high
number
travel
europ
would
like
lead
even
higher
widespread
risk
europ
rapid
assess
readi
eueea
laboratori
molecular
detect
demonstr
fast
implement
molecular
diagnost
european
specialis
laboratori
network
good
geograph
coverag
test
among
laboratori
network
studi
protocol
share
rapidli
earli
avail
posit
control
cov
specif
panel
via
evag
furthermor
survey
indic
great
willing
laboratori
provid
intern
diagnost
support
share
sequenc
contribut
monitor
viru
evolut
trace
transmiss
chain
howev
although
first
protocol
suggest
primerprob
sequenc
avail
fast
websit
figur
valid
panel
made
avail
evag
portal
soon
avail
primer
probe
posit
control
indic
import
initi
obstacl
test
implement
addit
lack
suffici
personnel
implement
valid
barrier
observ
respons
zika
viru
zikv
outbreak
america
relat
pheic
suggest
challeng
face
specialis
laboratori
respond
emerg
event
structur
natur
capacitywis
survey
indic
european
specialis
laboratori
prepar
current
situat
suggest
sensit
case
definit
current
use
would
creat
immedi
bottleneck
howev
remain
seen
realist
estim
particularli
view
coincid
season
epidem
peak
respiratori
pathogen
influenza
virus
depend
epidemiolog
develop
outbreak
whether
current
worldwid
control
strategi
contain
activ
case
find
sustain
indic
laboratori
capac
suffic
outbreak
turn
pandem
specialis
laboratori
effort
would
refocu
refer
activ
like
confirmatori
test
laboratori
surveil
includ
viru
characteris
provis
refer
materi
advic
gener
test
would
shift
firstlin
hospit
laboratori
current
capac
would
requir
rollout
test
specialis
laboratori
done
influenza
pandem
survey
show
proper
valid
specif
lack
vast
major
laboratori
implement
test
laboratori
indic
implement
test
without
avail
posit
control
import
assess
clinic
sensit
implement
test
possibl
earli
phase
laboratori
respons
due
time
absenc
posit
clinic
materi
europ
three
laboratori
without
posit
control
also
assess
analyt
sensit
test
legal
possibl
gener
data
protect
regul
gdpr
share
willing
share
posit
clinic
materi
among
network
laboratori
first
case
confirm
eueea
determin
speed
laboratori
address
clinic
sensit
implement
test
number
case
eueea
still
limit
properli
assess
actual
capabl
laboratori
detect
sub
clinic
case
provid
direct
correct
action
profici
test
extern
qualiti
assess
eqa
essenti
urgent
need
import
eqa
illustr
european
zikv
respons
time
implement
match
overal
good
capabl
forti
respond
laboratori
studi
indic
particip
assess
current
activ
ongo
assess
actual
capabl
within
laboratori
network
eqa
conclus
molecular
test
quickli
implement
eueea
countri
still
room
improv
especi
aspect
clinic
valid
specif
sensit
could
expect
consid
survey
taken
earli
phase
laboratori
respons
capabl
test
base
profici
panel
need
